1,464 Shares in United Therapeutics Corporation $UTHR Bought by Allstate Corp

Allstate Corp acquired a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the third quarter, HoldingsChannel.com reports. The institutional investor acquired 1,464 shares of the biotechnology company’s stock, valued at approximately $614,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in UTHR. NorthCrest Asset Manangement LLC lifted its position in shares of United Therapeutics by 4.8% during the third quarter. NorthCrest Asset Manangement LLC now owns 5,694 shares of the biotechnology company’s stock valued at $2,601,000 after buying an additional 262 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in shares of United Therapeutics by 10.0% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 6,693 shares of the biotechnology company’s stock worth $3,058,000 after acquiring an additional 609 shares in the last quarter. Sequoia Financial Advisors LLC lifted its position in United Therapeutics by 67.2% during the third quarter. Sequoia Financial Advisors LLC now owns 1,784 shares of the biotechnology company’s stock valued at $748,000 after acquiring an additional 717 shares during the last quarter. Maryland State Retirement & Pension System lifted its position in United Therapeutics by 7.3% during the third quarter. Maryland State Retirement & Pension System now owns 2,189 shares of the biotechnology company’s stock valued at $918,000 after acquiring an additional 148 shares during the last quarter. Finally, Retirement Investment Advisors Inc. acquired a new stake in United Therapeutics in the third quarter valued at approximately $252,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Up 0.5%

United Therapeutics stock opened at $472.06 on Friday. The stock has a 50-day moving average price of $487.61 and a 200 day moving average price of $412.88. The company has a market capitalization of $20.33 billion, a price-to-earnings ratio of 17.89, a price-to-earnings-growth ratio of 2.52 and a beta of 0.84. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $519.99.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company had revenue of $799.50 million for the quarter, compared to the consensus estimate of $812.87 million. During the same quarter in the prior year, the company earned $6.39 EPS. United Therapeutics’s quarterly revenue was up 6.8% on a year-over-year basis. Research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on UTHR shares. Wells Fargo & Company upped their price target on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. UBS Group upped their target price on United Therapeutics from $600.00 to $645.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Royal Bank Of Canada increased their price target on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Finally, Jefferies Financial Group restated a “buy” rating and set a $575.00 price objective on shares of United Therapeutics in a report on Wednesday, November 19th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and an average price target of $509.50.

Insider Buying and Selling at United Therapeutics

In related news, EVP Paul A. Mahon sold 8,300 shares of the firm’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $469.89, for a total transaction of $3,900,087.00. Following the completion of the transaction, the executive vice president owned 36,781 shares of the company’s stock, valued at $17,283,024.09. This trade represents a 18.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Christopher Causey sold 1,000 shares of the business’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $510.00, for a total transaction of $510,000.00. Following the transaction, the director owned 4,190 shares of the company’s stock, valued at $2,136,900. This represents a 19.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 563,364 shares of company stock worth $266,247,272 over the last ninety days. 10.30% of the stock is owned by insiders.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.